All Updates

All Updates

icon
Filter
Partnerships
AbCellera and Moderna team up for AI drug discovery
AI Drug Discovery
Sep 15, 2021
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
Product updates
Uber releases five new features for holiday travel season
Travel Tech
Yesterday
AI Drug Discovery

AI Drug Discovery

Sep 15, 2021

AbCellera and Moderna team up for AI drug discovery

Partnerships

  • Canadian AI drug discovery company AbCellera has entered into a multi-year, multi-target collaboration with American biotechnology company Moderna Therapeutics to discover and develop novel antibodies across various indications. The terms and financial details of the collaboration have not been disclosed.

  • The partnership will leverage AbCellera’s AI-based antibody discovery platform and Moderna’s expertise in ribonucleic acid (RNA) therapies to investigate natural immune responses and develop messenger RNA (mRNA)-encoded antibodies for up to six targets selected by Moderna. 

  • As per the agreement, AbCellera will receive research payments along with other milestone payments throughout the partnership period. It will also be eligible for royalties on net sales of the products. Moderna will possess the rights to develop and commercialize the antibodies resulting from the partnership. 

  • AbCellera recently partnered with two US-based biotechnology companies, EQRx and Tachyon Therapeutics, to jointly discover and develop novel antibodies. Last year, the company partnered with Eli Lilly to develop therapies for Covid-19. 

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.